Europe Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)
Market Introduction
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body.
Get more information on this report :
Market Overview and Dynamics
The Europe multiple sclerosis therapeutics market is expected to reach US$ 13,281.11 million by 2027 from US$ 8,423.83 million in 2019; it is estimated to grow at a CAGR of 6.0% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as increasing awareness about multiple sclerosis amongst population, and development and launch of innovative products. However, the high cost of the multiple sclerosis treatment hinders the market growth.
In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of multiple sclerosis disease and help the patients in making educated decisions regarding its treatment. Also, the National MS Society created and launched the “MS Kills Connection > < Connection Kills MS” campaign to connect people suffering from MS, people who treat MS patients, and people who run activities to create a world free of MS. Similarly, several players operating in the multiple sclerosis therapeutics market are developing and launching new products. The strategy of geographic and manufacturing capacity expansion, along with the product launches, helps companies cater to a broad customer base. Such developments and launches of new products are emerging as a key trend in the Europe multiple sclerosis therapeutics market.
Europe is recording the growing number of COVID-19 cases. Due to the second wave of COVID-19 outbreak, many countries' governments are working toward boosting up their cell therapies, gene therapies, and regenerative medicines produced by various companies. Increasing COVID-19 cases affect the diagnosis and treatment of diseases due to the diversification of the medical workforce and decision to focus on treating the critically ill patients. Due to the current pandemic, many universities and research institutes stopped clinical trials, as scientists are shifting their focus on controlling the COVID-19 outbreak and are working hard to better study the virus. Thus, the growing focus on COVID-19 outbreak is hindering on the market growth.
Key Market Segments
The Europe multiple sclerosis therapeutics market, by drug class, is bifurcated into immunosuppressant and immunomodulators. The immunomodulators segment held a larger share of the market in 2019, whereas the immunosuppressants segment is anticipated to register a higher CAGR in the market during the forecast period.
The Europe multiple sclerosis therapeutics market, by route of administration, is bifurcated into injectable and oral. The injectable segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR in the market during the forecast period.
Based on distribution channel, the Europe multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019. However, the e-commerce segment is estimated to register the highest CAGR in the market during the forecast period.
Major Sources and Companies Listed
Some of the primary and secondary sources associated with this report on the Europe multiple sclerosis therapeutics market are the European Centre for Disease Prevention and Control (ECDC), European Academy of Neurology (EAN) and European Medicines Agency (EMA).
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of Europe multiple sclerosis therapeutics market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the Europe multiple sclerosis therapeutics market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Europe multiple sclerosis therapeutics market.
EUROPE MULTIPLE SCLEROSIS THERAPEUTICS MARKET SEGMENTATION
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Country
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Multiple Sclerosis Therapeutics Market – By Drug Class
1.3.2 Europe Multiple Sclerosis Therapeutics Market – By Route Of Administration
1.3.3 Europe Multiple Sclerosis Therapeutics Market – By Distribution Channel
1.3.4 Europe Multiple Sclerosis Therapeutics Market – By Country
2. Multiple Sclerosis Therapeutics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Multiple Sclerosis Therapeutics– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinions
5. Multiple Sclerosis Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis
6. Multiple Sclerosis Therapeutics Market – Europe Analysis
6.1 Europe Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis
7. Multiple Sclerosis Therapeutics Market Analysis – By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8. Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 – Europe Analysis
10.1 Europe: Multiple Sclerosis Therapeutics Market
10.1.1 Overview
10.1.2 Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.1.3 Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.1 Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.2 Germany Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.1.3.3 Germany Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.1.3.4 Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.4 UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.1 UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.2 UK Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.1.4.3 UK Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.1.4.4 UK Multiple Sclerosis Therapeutics Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.5 France: Market – Revenue and Forecast to 2027 (USD Million)
10.1.5.1 France: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.5.2 France Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.1.5.3 France Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.1.5.4 France Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.6 Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.6.1 Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.6.2 Spain Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.1.6.3 Spain Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.1.6.4 Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.7 Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Italy Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.1.7.3 Italy Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.1.7.4 Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.8 Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
10.1.8.3 Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
10.1.8.4 Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Multiple Sclerosis Therapeutics Market
11.1 Europe: Impact Assessment Of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Horizon Therapeutics plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Biogen
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 2. Germany Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 3. Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 4. UK Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 5. UK Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 6. UK: Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million).
Table 7. France Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 8. France Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 9. France Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 10. Spain Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 11. Spain Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Italy Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 14. Italy Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 16. Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 17. Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 18. Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 19. Organic Developments Done By Companies
Table 20. Inorganic Developments Done by Companies
Table 21. Glossary of Terms, Multiple sclerosis therapeutics Market
LIST OF FIGURES
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share of Multiple Sclerosis Therapeutics Market
Figure 5. Europe Multiple Sclerosis Therapeutics Market – Leading Country Markets (US$ Million)
Figure 6. Europe PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Europe Multiple Sclerosis Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
Figure 19. Europe: Multiple Sclerosis Therapeutics Market, by Key Country – Revenue (2019) (USD Million)
Figure 20. Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 21. Germany: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 22. UK: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 23. France: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 24. Spain: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 25. Italy: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 26. Rest of Europe: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. Impact of COVID-19 Pandemic in European Country Markets
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe multiple sclerosis therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe multiple sclerosis therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.